Bladder cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• HER2 47
• PD-1 19
• PD-L1 10
• FGFR 10
• PI3K 1
• TP53 1
• AKT 0
• mTOR 0
• STAT3 0
• MAPK 0
• PPAR 0
• CTNNB1 0
• TROP2 1
• EGFR 0
• ERK 0
• MYC 0
• AMPK 0
• CTLA-4 1
• PTEN 0
• VEGF 4
• STING 0
• GPX4 0
• MMP-9 0
• BCL-2 0
• YAP 0
• IL-6 0
• JAK 0
• NRF2 0
• PSMA 1
• AR 0
• B7-H3 0
• CDK4/6 1
• HIF-1 0
• HSP90 0
• IL-15 1
• JNK 0
• PARP 0
• ALK 0
• ARID1A 2
• BRCA1 1
• COX-2 0
• HDAC 1
• IDH 1
• KRAS 0
• LAG-3 0
• METTL3 1
• PIK3CA 0
• PKM2 0
• SGLT2 0
• TERT 0
• AXL 0
• BRAF 1
• BRCA2 1
• EZH2 0
• FAK 0
• FTO 0
• GLP-1 0
• HMGB1 0
• IDO1 0
• MDM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 2,077 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Updated 5 Nov 2026

  “\< 75 % participation”Registry text, quoted unchanged. Source

• Terminated

  Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

  NCT06571708· Columbia University· Updated 3 Nov 2026

  “Change in standard of care treatment for muscle-invasive bladder cancer”Registry text, quoted unchanged. Source

• Terminated

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Updated 29 Oct 2026

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”Registry text, quoted unchanged. Source

• Terminated

  A Study of E7130 in Participants With Solid Tumors

  NCT03444701· Eisai Co., Ltd.· Updated 23 Oct 2026

  “The trial was prematurely terminated due to the sponsor's decision.”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of Naloxegol in the Prevention of POI After Cystectomy

  NCT04219046· Institut Paoli-Calmettes· Updated 14 Oct 2026

  “the industrial partner withdrew from the study”Registry text, quoted unchanged. Source

• Terminated

  TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors

  NCT06373419· Thunder Bay Regional Health Research Institute· Updated 1 Oct 2026

  “Lack of enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

  NCT06290687· Case Comprehensive Cancer Center· Updated 24 Sept 2026

  “PI left institution”Registry text, quoted unchanged. Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

  NCT07414992· Memorial Sloan Kettering Cancer Center· Updated 3 Sept 2026

  “The sponsor is no longer supporting the trial because they are no longer interested in studying the drug in the target patient population.”Registry text, quoted unchanged. Source

• Withdrawn

  STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy

  NCT07655284· Brigham and Women's Hospital· Updated 13 Aug 2026

  “Study withdrawn prior to enrollment. Principle Investigator changed institutions prior to obtaining IRB approval.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors

  NCT06660654· Daiichi Sankyo Inc.· Source

• A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

  NCT04660344· Hoffmann-La Roche· Source

• The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· National Cancer Institute (NCI)· Source

• Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

  NCT05987241· National Cancer Institute (NCI)· Source

• A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)

  NCT07829783· Merck Sharp & Dohme LLC· Source

• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

  NCT00026884· National Cancer Institute (NCI)· Source

• Evaluation for NCI Surgery Branch Clinical Research Protocols

  NCT00001823· National Cancer Institute (NCI)· Source

• Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor

  NCT07165236· Osijek University Hospital· Source

• Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

  NCT04628767· National Cancer Institute (NCI)· Source

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

  NCT06637423· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 22
• Organoids 11
• Mendelian Randomization Analysis 15
• CRISPR-Cas Systems 14
• Gene Expression Profiling 78
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 7
• Exome Sequencing 3
• Proteomics 27
• Metabolomics 15
• Mass Spectrometry 4
• Flow Cytometry 17
• Immunohistochemistry 93
• Liquid Biopsy 23
• Circulating Tumor DNA 33
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 40
• Machine Learning 44
• Deep Learning 24
• Cohort Studies 76
• Genome-Wide Association Study 18

• Development and validation of a ferroptosis and metabolic reprogramming gene signature for risk stratification in bladder urothelial carcinoma: A retrospective multicohort study.

  Medicine (Baltimore), Oct 2026

• Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer.

  Front Immunol, Oct 2026

• Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer.

  Front Immunol, Sept 2026

• Spatial Transcriptomics of Micropapillary, Plasmacytoid, and Sarcomatoid Urothelial Carcinoma Reveals Distinct Molecular Landscapes.

  Lab Invest, Aug 2026

• [Development of a 36-gene signature for predicting recurrence in non-muscle-invasive bladder cancer and validation in a Chinese cohort].

  Beijing Da Xue Xue Bao Yi Xue Ban, Aug 2026

• Lipid-Rich Urothelial Carcinoma: A Contemporary Clinicopathologic Study of 40 Patients With Transcriptional Tumor Profiling.

  Am J Surg Pathol, Aug 2026

• Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer.

  Int Immunopharmacol, Aug 2026

• A bladder cancer-associated gene signature for exploratory qPCR-based survival stratification in NAC-Treated muscle-invasive bladder cancer.

  J Transl Med, Jul 2026

• Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches.

  BMC Cancer, Jul 2026

• Integrative analysis identifies candidate biomarkers for bladder cancer: evidence from genomic and clinical validation.

  Mol Biol Rep, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.